

Mark N Kirstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4064647/publications.pdf>

Version: 2024-02-01

27
papers

860
citations

759233

12
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

1260
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). <i>Oncogene</i> , 1997, 14, 2175-2188. | 5.9 | 455 |
| 2 | High-performance liquid chromatographic method for the determination of gemcitabine and 2â€²,2â€²-difluorodeoxyuridine in plasma and tissue culture media. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 835, 136-142. | 2.3 | 59 |
| 3 | Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 269-276. | 2.3 | 42 |
| 4 | Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). <i>Breast Cancer Research and Treatment</i> , 2016, 155, 501-512. | 2.5 | 35 |
| 5 | Severe Electrolyte Disturbances After Hyperthermic Intraperitoneal Chemotherapy: Oxaliplatin Versus Mitomycin C. <i>Annals of Surgical Oncology</i> , 2011, 18, 174-180. | 1.5 | 34 |
| 6 | Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. <i>Pharmacogenomics</i> , 2012, 13, 1009-1021. | 1.3 | 26 |
| 7 | Exposureâ€“response relationships for oxaliplatin-treated colon cancer cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 37-44. | 1.4 | 24 |
| 8 | Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. <i>Translational Research</i> , 2016, 175, 103-115.e4. | 5.0 | 22 |
| 9 | Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 291-299. | 2.3 | 17 |
| 10 | Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 89-93. | 2.3 | 16 |
| 11 | Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 217-225. | 2.5 | 14 |
| 12 | Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 721-731. | 2.3 | 14 |
| 13 | Pharmacokineticâ€“pharmacodynamic modelling of acute Nâ€™terminal pro Bâ€™type natriuretic peptide after doxorubicin infusion in breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 773-783. | 2.4 | 12 |
| 14 | CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0062321. | 3.2 | 12 |
| 15 | Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine. <i>AAPS Journal</i> , 2012, 14, 1-9. | 4.4 | 11 |
| 16 | Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 433-438. | 2.3 | 8 |
| 17 | Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 153-161. | 1.6 | 7 |
| 18 | Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 597-602. | 1.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 955-964. | 2.4 | 7 |
| 20 | Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. <i>Lung Cancer</i> , 2007, 58, 196-204. | 2.0 | 6 |
| 21 | Cap-dependent translation blockade and fixed dose-rate gemcitabine: Interaction in an in vitro bioreactor system. <i>Cancer Letters</i> , 2009, 284, 37-46. | 7.2 | 6 |
| 22 | Combinatorial Pharmacologic Effects of Gemcitabine and its Metabolite dFdU. <i>ChemMedChem</i> , 2011, 6, 457-464. | 3.2 | 6 |
| 23 | Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 387-391. | 2.3 | 5 |
| 24 | Topoisomerase I interactive agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2002, 20, 99-123. | 0.5 | 5 |
| 25 | Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 3.2 | 4 |
| 26 | Predictive Value of C-reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 855-862. | 2.0 | 3 |
| 27 | Enhanced Sensitivity Method for Measuring Gemcitabine in Human Plasma. <i>Chromatographia</i> , 2010, 72, 1005-1008. | 1.3 | 1 |